[The clinico-immunological efficacy of the likopid treatment of chronic bronchitis patients]. 1998

A M Borisova, and N Kh Setdikova, and B V Pinegin, and A V Kulakov, and N M Golubeva

OBJECTIVE Elucidation of likopid effect on clinical and immunological pictures in patients with chronic bronchitis (CB). METHODS A trial of 52 CB patients in remission and exacerbation. 2 schemes of likopid treatment were used: 1 mg/day for 10 days (a course dose 10 mg); 10 mg/day for 6 days (a course dose 60 mg). Clinical and laboratory parameters, systemic immunity (measurement of lymphocyte subpopulations, levels of serum IgA, IgM and IgG, functional activity of peripheral blood phagocytes). RESULTS The 10 mg and 60 mg courses of likopid produced prolongation of remission to 5-6 months in 66% of CB patients in exacerbation and in 80% of patients in remission, respectively. 10 mg of likopid in exacerbation and 60 mg in remission promoted normalization of functional activity of blood phagocytes. CONCLUSIONS Likopid administration for CB in a 10 mg course dose in exacerbation and 60 mg course in remission prolongs CB remission to 5-6 months and promoted normalization of phagocytic functional activity.

UI MeSH Term Description Entries
D007136 Immunoglobulins Multi-subunit proteins which function in IMMUNITY. They are produced by B LYMPHOCYTES from the IMMUNOGLOBULIN GENES. They are comprised of two heavy (IMMUNOGLOBULIN HEAVY CHAINS) and two light chains (IMMUNOGLOBULIN LIGHT CHAINS) with additional ancillary polypeptide chains depending on their isoforms. The variety of isoforms include monomeric or polymeric forms, and transmembrane forms (B-CELL ANTIGEN RECEPTORS) or secreted forms (ANTIBODIES). They are divided by the amino acid sequence of their heavy chains into five classes (IMMUNOGLOBULIN A; IMMUNOGLOBULIN D; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M) and various subclasses. Globulins, Immune,Immune Globulin,Immune Globulins,Immunoglobulin,Globulin, Immune
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010586 Phagocytes Cells that can carry out the process of PHAGOCYTOSIS. Phagocyte,Phagocytic Cell,Phagocytic Cells,Cell, Phagocytic,Cells, Phagocytic
D001991 Bronchitis Inflammation of the large airways in the lung including any part of the BRONCHI, from the PRIMARY BRONCHI to the TERTIARY BRONCHI. Bronchitides
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000119 Acetylmuramyl-Alanyl-Isoglutamine Peptidoglycan immunoadjuvant originally isolated from bacterial cell wall fragments; also acts as pyrogen and may cause arthritis; stimulates both humoral and cellular immunity. Mur-NAc-L-Ala-D-isoGln,Muramyl Dipeptide,Acetylmuramyl Alanyl Isoglutamine,N-Acetyl-Muramyl-L-Alanyl-D-Glutamic-alpha-Amide,N-Acetylmuramyl-L-Alanyl-D-Isoglutamine,Alanyl Isoglutamine, Acetylmuramyl,Dipeptide, Muramyl,Isoglutamine, Acetylmuramyl Alanyl,Mur NAc L Ala D isoGln,N Acetyl Muramyl L Alanyl D Glutamic alpha Amide,N Acetylmuramyl L Alanyl D Isoglutamine
D000276 Adjuvants, Immunologic Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. Immunoactivators,Immunoadjuvant,Immunoadjuvants,Immunologic Adjuvant,Immunopotentiator,Immunopotentiators,Immunostimulant,Immunostimulants,Adjuvant, Immunologic,Adjuvants, Immunological,Immunologic Adjuvants,Immunological Adjuvant,Adjuvant, Immunological,Immunological Adjuvants
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

A M Borisova, and N Kh Setdikova, and B V Pinegin, and A V Kulakov, and N M Golubeva
January 2001, Vestnik otorinolaringologii,
A M Borisova, and N Kh Setdikova, and B V Pinegin, and A V Kulakov, and N M Golubeva
January 1994, Terapevticheskii arkhiv,
A M Borisova, and N Kh Setdikova, and B V Pinegin, and A V Kulakov, and N M Golubeva
January 1985, Terapevticheskii arkhiv,
A M Borisova, and N Kh Setdikova, and B V Pinegin, and A V Kulakov, and N M Golubeva
March 1983, Vestnik dermatologii i venerologii,
A M Borisova, and N Kh Setdikova, and B V Pinegin, and A V Kulakov, and N M Golubeva
March 1983, Vrachebnoe delo,
A M Borisova, and N Kh Setdikova, and B V Pinegin, and A V Kulakov, and N M Golubeva
August 1992, Likars'ka sprava,
A M Borisova, and N Kh Setdikova, and B V Pinegin, and A V Kulakov, and N M Golubeva
March 1985, Vrachebnoe delo,
A M Borisova, and N Kh Setdikova, and B V Pinegin, and A V Kulakov, and N M Golubeva
January 1995, Likars'ka sprava,
A M Borisova, and N Kh Setdikova, and B V Pinegin, and A V Kulakov, and N M Golubeva
January 1998, Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic],
A M Borisova, and N Kh Setdikova, and B V Pinegin, and A V Kulakov, and N M Golubeva
January 1988, Terapevticheskii arkhiv,
Copied contents to your clipboard!